The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Neuroendocrine cells in tumour growth of the prostate.
Open accessAbstract
The prognostic significance of neuroendocrine differentiation in prostatic malignancy is controversial, but the results of recent studies with markers such as chromogranin A and neurone-specific enolase suggest that neuroendocrine differentiation, as reflected by increased tissue expression or blood concentrations of these neuroendocrine secretory products, is associated with a poor prognosis, tumour progression, and androgen independence. As all malignant neuroendocrine cells are devoid of androgen receptors and the expression of neuroendocrine cells is not suppressed by androgen ablation, clonal propagation of androgen receptor-negative neuroendocrine cells may have an important role in the development of androgen-independent prostatic carcinoma. This has significant implications for the treatment of prostate cancer, because several of the hormones that are secreted by neuroendocrine differentiated, malignant prostatic cells are potential candidates for use in drug treatment. A limited number of hormones have been tested in this context, in particular somatostatin, bombesin, and serotonin. As there is currently no successful treatment for differentiated prostate cancer, new therapeutic procedures and trials need to be developed to test drugs based on neuroendocrine hormones or their antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death.
Hockenbery, D. M., Zutter, M., Hickey, W., Nahm, M., & Korsmeyer, S. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.16.6961 · Cited by 1,252 · cited 1×
“The bcl-2 proto-oncogene prevents apoptosis and is expressed by prostatic basal cells that are known to be androgen independent (Hockenbery et al. 1991).”
Background
Cited by
Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation
Epstein, J. I., Amin, M. B., Beltran, H., Lotan, T. L., Mosquera, J.-M., Reuter, V. E., Robinson, B. D., Troncoso, P., & Rubin, M. A. (2014) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000208 · Cited by 569
Small cell carcinoma of the prostate
Nadal, R., Schweizer, M., Kryvenko, O. N., Epstein, J. I., & Eisenberger, M. A. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.21 · Cited by 276
Neuroendocrine Differentiation in Prostate Cancer: Implications for New Treatment Modalities
Vashchenko, N., & Abrahamsson, P.-A. (2005) · European Urology · doi:10.1016/j.eururo.2004.09.007 · Cited by 260
Self-citationJin, R. J., Lho, Y., Connelly, L., Wang, Y., Yu, X., Saint Jean, L., Case, T. C., Ellwood-Yen, K., Sawyers, C. L., Bhowmick, N. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0107 · Cited by 182
Yang, J. C., Ok, J.-H., Busby, J. E., Borowsky, A. D., Kung, H.-J., & Evans, C. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-0442 · Cited by 70
Morell, C., Bort, A., Vara-Ciruelos, D., Ramos-Torres, Á., Altamirano-Dimas, M., Díaz-Laviada, I., & Rodríguez-Henche, N. (2016) · PLOS ONE · doi:10.1371/journal.pone.0162977 · Cited by 50
Human stroma and epithelium co-culture in a microfluidic model of a human prostate gland
Jiang, L., Ivich, F., Tahsin, S., Tran, M., Frank, S. B., Miranti, C. K., & Zohar, Y. (2019) · Biomicrofluidics · doi:10.1063/1.5126714 · Cited by 31
Metadata
- Authors
- Abrahamsson, P. A.
- Venue
- Endocrine-related cancer
- Publisher
- Bioscientifica
- Published
- 1999-12
- Volume
- 6
- Issue
- 4
- Pages
- 503-519
- ISSN
- 1351-0088 (ISSN-L)
- OpenAlex
- W2114693836
- Cited by
- 247
- References
- 1
- FWCI
- 7.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.